FIT Biotech Oy: FIT Biotech’s Certified Adviser to change – FIT Biotech

Reports and Releases

FIT Biotech Oy: FIT Biotech’s Certified Adviser to change

FIT Biotech Oy
 
Company release September 9, 2016 at 8:30 am EET       
 
 
FIT Biotech's Certified Adviser to change

The shares of FIT Biotech are listed for trading on Nasdaq Helsinki First North Finland, which requires the nomination of a Certified Adviser.

Effective September 10, 2016 FIT Biotech's Certified Adviser is Aalto Capital Partners Oy.

The company's Certified Adviser until September 10, 2016 is Translink Corporate Finance Oy.

FIT BIOTECH OY

Board of Directors

Juha Vapaavuori
Chairman of the Board of Directors
FIT Biotech Oy
Tel: 050 372 0824
E-mail: juha.vapaavuori@sitra.fi


Certified Adviser as of September 10, 2016: Aalto Capital Partners Oy, telephone +358 40 5877000

Certified Adviser until September 10, 2016: Translink Corporate Finance Oy, telephone +358 20 743

FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland market maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
Nasdaq Helsinki
Principal media
www.fitbiotech.com

Back to list